Exelixis, Inc. (EXEL)

Exelixis is a pharmaceutical company that discovers, develops, and commercialises small-molecule drugs designed to target specific cancer pathways—the kind of precision oncology play that operates in one of the largest and highest-margin drug markets on Earth.

Exelixis began as a discovery-stage biotech company in the Bay Area in 1999, part of the dot-com-era wave of life-science startups that wagered they could mine the human genome and the protein interactions it encodes for therapeutic targets. Two decades on, the company has transitioned from pure research into a commercial pharmaceutical business—one that owns and markets approved drugs rather than licensing them out, and that runs a global sales force responsible for pushing its products into hospitals and oncologist practices worldwide.

The targeted cancer approach

The company’s main product is cabozantinib, a small-molecule tyrosine kinase inhibitor—a class of drug that blocks the signalling proteins cancer cells use to grow and divide. Exelixis markets it under two trade names: Cometriq for medullary thyroid cancer and Cabometyx for renal cell carcinoma and hepatocellular carcinoma. The drug works by shutting down multiple pathways that fuel tumour growth; it is not a cure, but it extends survival and reduces disease progression in patients whose cancers express the relevant mutations or markers.

The regulatory pathway for a cancer drug is brutal. It requires phase 1 (safety in healthy volunteers), phase 2 (early efficacy and dosing signals), and phase 3 (head-to-head trials against the current standard of care) in patient populations that are often quite small. The trials themselves can take a decade or more; the FDA may approve a drug on an accelerated timeline if the data are compelling, but approval is not guaranteed, and late-stage trial failures—common in oncology—can wipe out billions in invested capital. Exelixis has navigated this gauntlet successfully with cabozantinib and several other candidates, bringing multiple drugs through to regulatory approval and commercial launch.

Revenue drivers and patient economics

Exelixis’ revenue is almost entirely from Cabometyx and Cometriq—these two drugs account for the vast majority of sales. Oncology drugs, particularly newer precision therapies, command very high prices; an annual course of treatment for a renal cell carcinoma patient might cost tens of thousands of dollars. In the United States, much of that cost is absorbed by insurance; in international markets, pricing is set in negotiation with government health systems and varies wildly. The margin on a drug once it is approved and manufacturing is running is very high—the incremental cost of producing and distributing a capsule is small relative to the price charged—but the capital and R&D costs upstream were enormous and are sunk.

Exelixis is dependent on its approved drugs’ market adoption and competitive positioning. Renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer are rare to modestly rare cancers; the addressable patient population is measured in thousands per year globally, not millions. That means Exelixis must achieve high penetration in the patients for whom the drug is approved and indicated, and it must be able to defend its drugs against new competitors as other companies bring newer, potentially superior therapies to market. The company competes against pharmaceutical giants with larger sales forces and bigger R&D budgets; holding market share in a small indication requires clinical data, strong relationships with key opinion-leader oncologists, and excellent commercial execution.

The R&D pipeline and future bets

Beyond the approved drugs, Exelixis maintains a pipeline of compounds in clinical development. These are typically incremental improvements on the kinase inhibitor platform—new targets, better selectivity, attempts to overcome resistance mechanisms—rather than wholly new drug classes. The success rate in late-stage oncology trials is roughly 50 per cent; that is, roughly half of phase 3 trials fail. When a trial fails, the company often loses the bet entirely, and the capital invested is gone.

The company also operates a discovery platform that combines high-throughput screening, structure-based drug design, and cellular and molecular biology to identify new targets and leads. This is the traditional biotech R&D model: cast a wide net early, filter ruthlessly through expensive experiments and animal models, advance the most promising candidates into human trials, and accept that most will fail. The winners—like cabozantinib—can generate returns many multiples larger than the total invested; the losers cost time and money with nothing to show.

Risk and sustainability

Exelixis faces the risks inherent to all single-asset or two-asset pharmaceutical companies. If cabozantinib and Cometriq face generic or biosimilar competition, or if new competitive drugs with better safety or efficacy profiles capture market share, Exelixis’ revenue could decline rapidly and profoundly. The company is reinvesting heavily into R&D to build a more diverse pipeline, but that is expensive and outcomes are uncertain.

Patent protection matters enormously. Most oncology drugs have patent life extending into the 2030s or beyond, but that is not guaranteed; if a patent expires or is challenged and invalidated, a generic competitor can enter within months and typically capture the vast majority of volume and margin. Exelixis’ ability to sustain and grow revenue depends on either expanding indications for current drugs (pursuing approvals in additional cancer types), launching new pipeline candidates successfully, or both.

The company also carries regulatory risk. The FDA can require additional post-approval trials, impose safety restrictions, or withdraw approval if new safety signals emerge. And international regulatory pathways are less predictable; a drug approved in the United States may face delays or rejection elsewhere, narrowing the revenue opportunity.

How to research Exelixis

The company’s 10-K filing (SEC CIK 0000939767) breaks revenue by drug and geography and covers the key risks and pipeline stage-gates. The most important metric to monitor is cabozantinib revenue—both absolute growth and market-share data relative to competing therapies in renal cell carcinoma and hepatocellular carcinoma. Clinical trial readouts are material events; when Exelixis releases phase 3 data on a pipeline candidate, the market reprices the company based on whether the efficacy bars were met. Gross margin on approved drugs is typically very high but shrinks as competition arrives or as pricing pressure builds in managed-care contracting. Finally, R&D spending and pipeline progression through development stages reveal how aggressively the company is positioned for future growth, and whether new candidates are advancing or stalling.